Pigmentation Disorders
Case Letter
Unusual Bilateral Distribution of Neurofibromatosis Type 5 on the Distal Upper Extremities
Segmental neurofibromatosis, or neurofibromatosis type 5 (NF5), is a rare subtype of neurofibromatosis type 1 (NF1)(also known as von...
Latest News
Ruxolitinib repigments many vitiligo-affected body areas
Ruxolitinib is a Janus kinase 1/2 inhibitor that has been available for the treatment for atopic dermatitis for more than a year.
Cosmeceutical Critique
Artemisia capillaris extract
Various parts of the shrub Artemisia capillaris, found abundantly in China, Japan, and Korea, have been used in traditional medicine in...
Photo Challenge
Linear Hypopigmentation on the Right Arm
A 73-year-old woman presented to the dermatology clinic with hypopigmentation along the right arm. Her medical history was notable for prior...
Latest News
Hydroquinone, found in skin-lightening agents worldwide, linked with increased skin cancer risk
“The magnitude of the risk was surprising,” one of the study authors said.
Latest News
VTE risk not elevated in AD patients on JAK inhibitors: Study
The labels of JAK inhibitors include a boxed warning describing an increased risk of “serious heart-related events such as heart attack or stroke...
Latest News
Why it’s important for dermatologists to learn about JAK inhibitors
“We are going to be getting a lot more indications for these drugs,” Dr. Andrew Blauvelt said.
Latest News
Dermatologists share vitiligo breakthrough news with patients
For the first time, patients with vitiligo who have long lived with patches of skin that are without pigment can now have even skin tones on their...
Photo Challenge
Pigmented Papules on the Face, Neck, and Chest
A 46-year-old woman presented with multiple asymptomatic, flesh-colored, hyperpigmented papules on the face of 5 to 6 months’ duration that were...
Latest News
FDA approves topical ruxolitinib for nonsegmental vitiligo
Approval was based on the results of two phase 3 trials in 674 patients with nonsegmental vitiligo aged 12 years or older.
Conference Coverage
Ruxolitinib found to benefit adolescents with vitiligo up to one year
The manufacturer has submitted an application for approval to the FDA in patients ages 12 years and older, based on 24-week results.